Qyuns Therapeutics (HKG:2509) released data from its phase 2 trial for its drug for prurigo nodularis during a meeting of the Chinese Society of Dermatology, according to a Friday filing with the Hong Kong Stock Exchange.
The drug obtained breakthrough therapy designation on Jan. 31, the filing said.
Prurigo nodularis is a skin inflammation manifesting as itchiness, and the itchiness is more intense compared with atopic dermatitis, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments